Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an upsized underwritten public offering of 14,090,000 shares of its common stock at a public...
The S&P 500 Index ($SPX ) (SPY ) closed down by -0.69% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.22%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -1.68%....
Amylyx shares rally on promising avexitide, a GLP-1 receptor antagonist, data. But should you load up on AMLX stock on strength today? Let’s find out!
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of $350.0 million of shares of its common stock. In...
/Computer%20memory%20closeup%20by%20Nor%20Gal%20via%20Shutterstock.jpg)
The S&P 500 Index ($SPX ) (SPY ) is down by -0.61% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.76%. E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) is down by -0.42% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down by -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -1.17%. E-mini S&P futures...
LUCIDITY met FDA-agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will announce topline results from its Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia...
Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated...
Barchart Research What to Expect from AMLX Earnings AMLX Generated August 5, 2026 Current Price $21.85 EPS Estimate $$-0.36 Consensus Rating Strong Buy Average Move 4.87% Can Amylyx Still Call This a Pipeline...